CORRESP Filing
CytoMed Therapeutics Ltd
Date: June 20, 2025 · CIK: 0001873093 · Accession: 0001641172-25-015754
AI Filing Summary & Sentiment
Reasoning
Letter
VIA EDGAR Division of Corporation Finance Office of Life Sciences Washington, D.C. 20549 Attn: Mr. Tim Buchmiller Re: CytoMed Therapeutics Limited Registration Statement on Form F-3, as amended (File No. 333- 288033) Request for Acceleration of Effectiveness
Dear Sir,
In accordance with Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, CytoMed Therapeutics Limited hereby requests that the effectiveness of the above-referenced Registration Statement on Form F-3, as amended be accelerated to and that the Registration Statement become effective at 4:00 p.m., Eastern Time, on June 23, 2025, or as soon thereafter as practicable.
Very
truly yours,
CytoMed
Therapeutics Limited
Show Raw Text
CORRESP 1 filename1.htm CytoMed Therapeutics Limited 1 Commonwealth Lane #08-22 Singapore 149544 June 20, 2025 VIA EDGAR Division of Corporation Finance Office of Life Sciences U.S. Securities and Exchange Commission 100 F Street, NE Washington, D.C. 20549 Attn: Mr. Tim Buchmiller Re: CytoMed Therapeutics Limited Registration Statement on Form F-3, as amended (File No. 333- 288033) Request for Acceleration of Effectiveness Dear Sir, In accordance with Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, CytoMed Therapeutics Limited hereby requests that the effectiveness of the above-referenced Registration Statement on Form F-3, as amended be accelerated to and that the Registration Statement become effective at 4:00 p.m., Eastern Time, on June 23, 2025, or as soon thereafter as practicable. Very truly yours, CytoMed Therapeutics Limited By: /s/ Choo Chee Kong Name: Choo Chee Kong Title: Chairman and Director